How would you manage patients with HER2+ breast CA receiving adjuvant trastuzumab who develop severe infusion reactions requiring medical intervention?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • Her2+ • Breast Cancer, Non-metastatic

Would you change to a SQ biosimilar, continue with premedication alone, or switch to a different anti-HER2 agent?

Related Questions

What would you recommend regarding HRT use in a patient with history of HR-, HER2+ breast cancer dealing with post-menopausal symptoms?

Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?

Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?

How do you manage steroid refractory pneumonitis due to docetaxel or trastuzumab?

Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?

For Her2+ Stage I T1cN0 patients where neoadjuvant therapy is desired to select out patients for post-operative TDM1, is it reasonable to de-escalate neoadjuvant therapy to THP as opposed to TCHP?

In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?

Would you offer systemic therapy (TH) to a patient with HER2+ (3+), HR- high grade microinvasive breast cancer with single focus or multifocal?

How would you treat a patient with T1c HR-, HER2+ breast cancer, stage IV, with involvement of multiple bilateral axillary nodes and no evidence of distant metastasis?

Is there an increaed risk of cancer when using spironolactone in patients with hormone positive breast cancer?